Multiple organ relapse in primary de novo CD5+ diffuse large B cell lymphoma of the bone after a complete response

DOI Web Site PubMed 14 References

Bibliographic Information

Other Title
  • 多臓器に再発を認めた，大腿骨原発ｄｅ　ｎｏｖｏ　ＣＤ５陽性びまん性大細胞型Ｂ細胞リンパ腫
  • 症例 多臓器に再発を認めた,大腿骨原発de novo CD5陽性びまん性大細胞型B細胞リンパ腫
  • ショウレイ タゾウキ ニ サイハツ オ ミトメタ ダイタイコツ ゲンパツ de novo CD5 ヨウセイビマンセイ ダイ サイボウガタ B サイボウ リンパ シュ

Search this article

Abstract

A 57-year-old woman was admitted with swelling of the femur. MRI showed that an intramedullary lesion had expanded from the trunk to the distal portion where it had formed an extramedullary tumor mass. An open biopsy showed diffuse proliferation of abnormal lymphoid cells. Immunohistochemical staining and flow cytometry demonstrated LCA+, CD3-, CD23-, CD79a+, CD5+, IgM+, IgD- and kappa+and cyclin D1-. FISH analysis did not detect t(11;14)(q13;q32). The final diagnosis was de novo CD5+ diffuse large B-cell lymphoma (DLBL) of the bone at clinical stage IEA. The patient suffered a pathological fracture in the femur after two courses of CHOP. The therapy was changed to ESHAP and irradiation. The result was assessed as a complete remission (CR). One month later, the patient presented with epigastric pain. MRI showed the tumor at the spleen and kidney and hydronephrosis due to pelvic lymphadenopathy, but did not show a tumor in the femur. An open biopsy of the pelvic lymph node showed relapse. The tumor and hydronephrosis disappeared and necrosis in the kidney was observed on MRI after ESHAP. De novo CD5+ DLBL appears to constitute a unique subset of DLBL with an aggressive clinical course and requires established therapeutic strategies.

Journal

  • Rinsho Ketsueki

    Rinsho Ketsueki 45 (2), 149-154, 2004

    The Japanese Society of Hematology

References(14)*help

See more

Keywords

Details 詳細情報について

Report a problem

Back to top